ABSI
NASDAQ · Biotechnology
Absci Corp
$2.85
-0.16 (-5.32%)
Financial Highlights (FY 2026)
Revenue
6.24M
Net Income
-142,025,863
Gross Margin
—
Profit Margin
-2,274.1%
Rev Growth
-1.8%
D/E Ratio
0.02
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | — | 58.4% | 58.4% |
| Operating Margin | -2,421.4% | -2,179.3% | -17.8% | -17.1% |
| Profit Margin | -2,274.1% | -2,160.4% | -15.3% | -17.3% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 6.24M | 6.35M | 58.57M | 57.07M |
| Gross Profit | — | — | 34.21M | 33.33M |
| Operating Income | -151,123,499 | -138,433,739 | -10,406,862 | -9,769,969 |
| Net Income | -142,025,863 | -130,100,027 | -8,944,093 | -9,875,873 |
| Gross Margin | — | — | 58.4% | 58.4% |
| Operating Margin | -2,421.4% | -2,179.3% | -17.8% | -17.1% |
| Profit Margin | -2,274.1% | -2,160.4% | -15.3% | -17.3% |
| Rev Growth | -1.8% | -1.8% | +10.3% | +2.6% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 5.14M | 5.14M | 100.48M | 118.62M |
| Total Equity | 226.43M | 226.43M | 298.85M | 311.81M |
| D/E Ratio | 0.02 | 0.02 | 0.34 | 0.38 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -122,710,467 | -118,651,342 | -15,160,350 | -13,058,914 |
| Free Cash Flow | — | — | -10,726,027 | -11,756,277 |